Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 1/20 | 0.60 |
| ▸ | LGALS3 | P17931 | 6/20 | 0.60 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.60 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.60 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.50 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.50 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-Acetylchitopentaose SCHEMBL20390680 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Chitodextrin SCHEMBL619917 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Triacetylchitotriose SCHEMBL425647 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Chitodextrin SCHEMBL19427436 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Triacetylchitotriose SCHEMBL974524 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Triacetylchitotriose SCHEMBL13040980 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| SCHEMBL20390674 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Chitodextrin SCHEMBL13046690 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Chitodextrin SCHEMBL21067311 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA | |
| Chitodextrin SCHEMBL7269765 | 1.00 | CD69 (0.60) | CD69LGALS3LGALS8LGALS4CHIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 587 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608859-A1 | GLYCOENGINEERED FC VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION | Ablynx N.V. (BE) | 2025-09-03 | — | — | EP | claimed |
| US-12343361-B2 | Compositions and methods for the treatment of hepatic diseases and disorders | LABYRINTH HOLDINGS, LLC (US) | 2025-07-01 | — | — | US | claimed |
| WO-2025088546-A1 | FC DOMAIN VARIANTS WITH ENHANCED FC RECEPTOR BINDING | ABLYNX N.V. (BE) | 2025-05-01 | — | — | WO | claimed |
| WO-2025032055-A1 | CYCLIC CARBAMATE COMPOUNDS FOR LIGATION | CARBOCALYX GMBH (DE) | 2025-02-13 | — | — | WO | claimed |
| CN-118525925-B | Application of yeast chitosan oligosaccharide in preparation of prawn feed additive | 中国海洋大学 | 2024-12-03 | — | — | CN | claimed |
| CN-118834246-A | Synthesis method of N-glycosyl oxazoline compound | 中国医学科学院药物研究所 | 2024-10-25 | — | — | CN | claimed |
| CN-118525925-A | Application of yeast chitosan oligosaccharide in preparation of prawn feed additive | 中国海洋大学 | 2024-08-23 | — | — | CN | claimed |
| CN-118460510-A | Cloning expression of enzyme Chi1 capable of efficiently degrading powder chitin and application thereof | 南京工业大学 | 2024-08-09 | — | — | CN | claimed |
| US-20240182586-A1 | Site-Specific Modification of Glycoproteins Through Transglutaminase-Mediated Conjugation | NORTHEASTERN UNIVERSITY | 2024-06-06 | — | — | US | claimed |
| US-20240166750-A1 | GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION | ABLYNX N.V. (BE) | 2024-05-23 | — | — | US | claimed |
| US-8470986-B2 | Method for production of sugar oxazoline derivative | TOHOKU UNIVERSITY (JP) | 2013-06-25 | — | — | US | claimed |
| US-20100121041-A1 | METHOD FOR PRODUCTION OF SUGAR OXAZOLINE DERIVATIVE | SEIKAGAKU CORPORATION (JP) | 2010-05-13 | — | — | US | claimed |
| EP-2123663-A1 | METHOD FOR PRODUCTION OF SUGAR OXAZOLINE DERIVATIVE | SEIKAGAKU CORPORATION (JP) | 2009-11-25 | — | — | EP | claimed |
| WO-2008153615-A2 | PREPARING CARBOHYDRATE MICROARRAYS AND CONJUGATED NANOPARTICLES | ADA TECHNOLOGIES, INC. (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080220988-A1 | Preparing carbohydrate microarrays and conjugated nanoparticles | ADA TECHNOLOGIES, INC. (US) | 2008-09-11 | — | — | US | claimed |
| US-5089394-A | Neisseria detection system | E-Y LABORATORIES, INC. (US) | 1992-02-18 | — | — | US | claimed |
| EP-0125039-B1 | ENZYMATIC PRODUCTION OF PHOSPHOLIPID-SACCHARIDE DERIVATIVES | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1989-02-15 | — | — | EP | claimed |
| US-4624919-A | Enzymatic production of phospholipid-saccharide derivatives | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1986-11-25 | — | — | US | claimed |
| EP-0125039-A2 | Enzymatic production of phospholipid-saccharide derivatives | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1984-11-14 | — | — | EP | claimed |
| EP-0122023-A1 | Microorganisms detection methods and the separation of agglutinated microorganisms, and a kit for use therein | E-Y LABORATORIES, INC. (US) | 1984-10-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121041-A1 | METHOD FOR PRODUCTION OF SUGAR OXAZOLINE DERIVATIVE | SORD, HSD17B14, TALDO1 | CD69 1683/4885LGALS3 912/4885LGALS8 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.